Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 4/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | OGFRL1 | Q5TC84 | 5/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 3/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3999603 | 0.88 | CXCR4 (0.53) | CXCR4OPRM1OGFRL1OPRD1OPRK1 | |
| SCHEMBL3373812 | 0.86 | CXCR4 (0.56) | CXCR4NOD2NOD1HDAC1HDAC6 | |
| SCHEMBL4939959 | 0.84 | CXCR4 (0.74) | CXCR4OPRM1OGFRL1OPRD1NOD2 | |
| SCHEMBL4885774 | 0.80 | CXCR4 (0.47) | CXCR4HDAC1HDAC6KDM1AFNTA | |
| SCHEMBL4885422 | 0.79 | CXCR4 (0.49) | CXCR4HDAC1HDAC6KDM1AFNTA | |
| Trifluoroacetic Acid SCHEMBL4889301 | 0.77 | CXCR4 (0.44) | CXCR4HDAC1HDAC6KDM1AFNTA | |
| SCHEMBL4716688 | 0.76 | HDAC1 (0.52) | CXCR4HDAC1HDAC6 | |
| SCHEMBL18661189 | 0.76 | CXCR4 (0.49) | CXCR4OPRM1OGFRL1OPRD1OPRK1 | |
| SCHEMBL2084608 | 0.76 | FNTA (0.51) | CXCR4HDAC1HDAC6KDM1AFNTA | |
| SCHEMBL14130832 | 0.76 | LMNA (0.57) | CXCR4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778231-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080096861-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1778231-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006020415-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096861-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | CXCR4 2/4885OPRM1 257/4885OGFRL1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.